GMAB ▲ +0.8% - Genmab A/S
$GMAB Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
04-OCT-2026 11:01 AM ET
Share this post
More filings for $GMAB
GMAB ▲ +7.6% - Genmab A/SOct 23, 2026GMAB ▼ -1.5% - Genmab A/SOct 7, 2026GMAB ▼ -1.5% - Genmab A/SOct 7, 2026GMAB - Genmab A/S - SEC Filing Update (05-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 6, 2026GMAB ▲ +11.0% - Genmab A/SOct 5, 2026
View full $GMAB filing history →💬 Comments
Loading comments…
Leave a comment